(0.10%) 5 522.25 points
(0.13%) 39 897 points
(0.20%) 19 791 points
(-0.02%) $81.61
(0.60%) $2.83
(-0.29%) $2 337.50
(0.19%) $29.58
(0.30%) $1 004.80
(0.01%) $0.932
(-0.06%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
0.09% $ 23.01
Live Chart Being Loaded With Signals
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 6.40M |
Średni wolumen | 1.13M |
Kapitalizacja rynkowa | 865.08M |
EPS | $-0.460 ( Q3 | 2023-11-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-15.04 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.377 (1.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 395 783 | Common Stock |
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 10 000 | 8.000% Series A Redeemable Preferred Stock |
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 299 430 | Common Stock Warrant (Right to Buy) |
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 85 750 | Common Stock Warrant (Right to Buy) |
2024-03-11 | Silvernail Lauren P | Sell | 5 000 | Common Stock |
INSIDER POWER |
---|
76.23 |
Last 96 transactions |
Buy: 30 137 007 | Sell: 5 308 481 |
Wolumen Korelacja
Harpoon Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Harpoon Therapeutics Inc Korelacja - Waluta/Towar
Harpoon Therapeutics Inc Finanse
Annual | 2022 |
Przychody: | $31.92M |
Zysk brutto: | $28.82M (90.30 %) |
EPS: | $-20.24 |
FY | 2022 |
Przychody: | $31.92M |
Zysk brutto: | $28.82M (90.30 %) |
EPS: | $-20.24 |
FY | 2021 |
Przychody: | $23.65M |
Zysk brutto: | $23.65M (100.00 %) |
EPS: | $-3.62 |
FY | 2020 |
Przychody: | $17.44M |
Zysk brutto: | $17.44M (100.00 %) |
EPS: | $-1.990 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Harpoon Therapeutics Inc
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej